Adán Pinto-Fernández

This study shows that the N-terminal truncation of USP18 generates a short isoform (SF) with distinct functions in muscle differentiation compared to the long isoform (LF).

This study identifies USP24 as a novel ISG15 cross-reactive deubiquitinase that de-ISGylates MOV10 to negatively regulate IFN-I production.

This study develops refined USP25/28 inhibitors that selectively target c-MYC driven squamous lung cancer cells with reduced off-target effects and toxicity.

The paper reverse-engineers a TCR to reduce cross-reactivity while maintaining potency by reverting specific residues.

This paper introduces a high-throughput activity proteomics pipeline for discovering deubiquitinase inhibitors, identifying potent and selective inhibitors with minimal optimization.

This paper introduces Huib32, a selective USP32 inhibitor, and two activity-based probes that modulate endosomal processes and provide tools for studying USP32 in cancer and neurodegenerative diseases.

The paper identifies a new E2 ubiquitin-conjugating enzyme in Plasmodium falciparum using a ubiquitin-activity based probe and validates its function through structural and biochemical analysis.

This study shows Huwe1 is essential for RIG-I-like receptor-mediated type I and III IFN induction by ubiquitinating key pathway components like TRAF5.

This study identifies altered plasma lipid profiles in rodent PCOS models using targeted mass spectrometry, revealing both similarities and differences compared to human PCOS.

This study investigates the structural dynamics of USP30 inhibition by a covalent inhibitor, revealing its binding mechanism and selectivity advantages over non-covalent inhibitors.

The paper shows KRAS mutations disrupt its interaction with LZTR1, affecting protein stability via the CUL3 ubiquitin ligase complex, contributing to oncogenesis.